News

The agreement is for Kashiv BioSciences’ biosimilar candidate to Genentech and Novartis AG’s Xolair (omalizumab) in the ...
Food allergy management is shifting from passive strategies — such as avoidance, carrying epinephrine and hope — to proactive ...
A new study published in the Journal of American Medical Association found that Rilzabrutinib decreased itching and hives ...
Among adults with severe asthma, those with healthy weight, overweight, obesity and severe obesity each had improvements in ...
A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...
Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ...
Scientists at Northwestern University have discovered a drug that could offer a new approach to treating life-threatening ...
A Northwestern study found that the asthma drug zileuton prevents food allergy anaphylaxis in mice by blocking allergen absorption in the gut. The research reveals a new mechanism driving allergic ...
In managing antihistamine-refractory chronic urticaria, omalizumab and remibrutinib stand out among the most effective treatments across multiple patient-important outcomes, followed by dupilumab ...
Kashiv BioSciences, LLC and MS Pharma today announced that the companies have entered into a license and supply agreement for ...
A drug used for asthma has been found to treat food allergies "shockingly well", in a breakthrough that could offer new protection for millions affected. This is the discovery of Northwestern Medicine ...
A drug already FDA-approved for asthma was found to nearly eliminate life-threatening allergic reactions to food allergens in ...